Zhongnan Hospital of Wuhan University in Wuhan, China, is at the heart of the outbreak of Covid-19, the disease caused by the new coronavirus SARS-CoV-2 that has shut down cities in China, as well as Iran, Italy, and South Korea. That’s forced the hospital to become a test bed for how quickly a modern medical center can adapt to a new infectious disease epidemic.
One experiment is underway in Zhongnan’s radiology department, where staff are using artificial intelligence software to detect visual signs of the pneumonia associated with Covid-19 on images from lung CT scans.
Haibo Xu, professor and chair of radiology at Zhongnan Hospital, says the software helps overworked staff screen patients and prioritize those most likely to have Covid-19 for further examination and testing. He emailed WIRED an audio file of himself answering a reporter’s questions about the project and answered other questions by email.
Detecting pneumonia on a scan doesn’t alone confirm a person has the disease, but Xu says doing so helps staff diagnose, isolate, and treat patients more quickly. The software “can identify typical signs or partial signs of Covid-19 pneumonia,” he wrote in an email. Doctors can then follow up with other examinations and lab tests to confirm a diagnosis of the disease. Xu says his department was quickly overwhelmed as the virus spread through Wuhan in January.
The software in use at Zhongnan was created by Beijing startup Infervision, which says its Covid-19 tool has been deployed at 34 hospitals in China and used to review more than 32,000 cases. The startup, founded in 2015 with funding from investors including early Google backer Sequoia Capital, is an example of how China has embraced applying artificial intelligence to medicine.
China’s government has urged development of AI tools for health care as part of sweeping national investments in artificial intelligence. China’s relatively lax rules on privacy allow companies such as Infervision to gather medical data to train machine-learning algorithms in tasks like reading scans more easily than US or European rivals.
Infervision created its main product, software that flags possible lung problems on CT scans, using hundreds of thousands of lung images collected from major Chinese hospitals. The software is in use at hospitals in China, and being evaluated by clinics in Europe, and the US, primarily to detect potentially cancerous lung nodules.
The firm began work on its Covid-19 detector early in the outbreak after noticing a sudden shift in how existing customers were using its lung scan reading software. In mid-January, not long after the US Centers for Disease Control advised against travel to Wuhan due to the new disease, hospitals in Hubei Province began employing a previously little used feature of Infervision’s software that looks for evidence of pneumonia, according to CEO Kuan Chen. “We realized it was coming from the outbreak,” he says.
Infervision’s staff in Beijing worked through the Lunar New Year holiday to tune their existing pneumonia detection algorithms to look more specifically for Covid-19 pneumonia. The company acquired images of the newly discovered pneumonia from Wuhan Tongji Hospital, one of the first to receive patients with the new disease, and a longstanding collaborator. The version of the software in use today was trained with more than 2,000 images from Covid-19 patients, Chen says.
Definitively diagnosing Covid-19 requires detecting the virus that causes it, SARS-CoV-2, in bodily fluids. Because testing takes some time, and some laboratories are becoming overloaded, clinical signs such as studying lung scans have become more important.
Official Covid-19 diagnosis guidelines released by China’s National Commission recommend using chest CT images as a major factor in diagnosis. Pneumonia associated with the disease, like other forms of viral pneumonia including that caused by SARS, produces shadows that radiologists call ground glass opacity.
A paper reviewing Covid-19 lung scans published last week by Hyungjin Kim, at Seoul National University Hospital in South Korea, concluded that AI software might lessen the burden on hospitals dealing with outbreaks by helping radiologists identify patients with the disease earlier.
Luke Oakden-Rayner, director of medical imaging research at the Royal Adelaide Hospital in Australia, says Infervision’s project makes him “both skeptical and cautiously optimistic.”
It’s plausible that algorithms could help staff reading scans to work faster, but that would only make a significant difference to patients if radiologists' time was a major bottleneck in a hospital’s operations. Xu says it has been an issue at Zhongnan Hospital, but that may not be the case in every hospital experiencing a rush of Covid-19 patients. More certain is that Infervision stands to raise its public profile with the project, Oakden-Rayner says.
Infervision’s work on coronavirus is part of a raft of experimentation in China triggered by the outbreak. Zhongnan recently began operating the hastily constructed, 1,600 bed, Leishenshan Hospital, one of two built from scratch in Wuhan to accommodate the surge of patients; it's also using Infervision’s new software. China’s clinical trial registry lists more than 230 studies targeting the disease, including using acupuncture.
Developing and testing new medical software or treatments within weeks isn’t ideal, but the mounting numbers of patients and deaths are forcing the hands of researchers in both the US and China. So far, there is no vaccine for the virus, and no standout treatment for its effects.
Chen, the Infervision CEO, says the Covid-19 pneumonia detector will eventually need formal approval from China’s National Medical Product Administration, which oversees health care AI tools. For now, the priority is to help doctors and patients. “There are always risks for any actions in a dangerous outbreak like this, but the risk of inaction is much greater,” he says.
Jeffrey Ding provided translation assistance.
Read more: https://www.wired.com/story/chinese-hospitals-deploy-ai-help-diagnose-covid-19/